Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Seagen filed SEC Schedule 14A outlining Pfizer $43 Bln M&A

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Apr 18, 2023 12:02pm

412 Views

Post# 35400783

Seagen filed SEC Schedule 14A outlining Pfizer $43 Bln M&A

Seagen retained Centerview Partners LLC (“Centerview”) as financial advisor to the Board in connection with the merger and the other transactions contemplated by the merger agreement.

Background of the Merger - Page 33

https://d18rn0p25nwr6d.cloudfront.net/CIK-0001060736/1e7d9948-6569-44a4-ad58-1d1ae6840511.pdf#page40

<< Previous

Bullboard Posts

Next >>

A PGM mining stock with value written all over it